19 pharmaceutical companies participate in the research and development of new coronavirus vaccine, and some products enter the animal experiment stage

[trends of pharmaceutical network industry] with the continuous introduction of vaccine products, those infectious diseases that once made people feel scared are still in history books From SARS, mers to new coronavirus, this epidemic is the third time in the new century that we are facing the sudden attack of coronavirus In the face of fierce opponents, can vaccines play a significant role in this epidemic? Novel coronavirus pneumonia vaccine was developed by 19 units in February 12th, including the following: a number of listed companies, including flying birds, Hua Lan biology, Liaoning Cheng Da, Kangtai biology, Conchino biology, Watson biology, etc Zhifei biology Zhifei biology has one of the A-share rich vaccine product echelons At present, there are 22 products under research and more than 10 are in the clinical stage, among which there are several heavyweight products: 1) 15 valent pneumonia vaccine: phase I clinical has been completed, and it is expected to start phase III clinical enrollment in 2020 The product is currently at a high price in China, and it is expected to be a billion net profit product; 2) Human diploid rabies vaccine: it is expected to complete the third phase of clinical trials in 2020, and it is expected to report production around the end of 2020, with a net profit of 500 million yuan; 3) tetravalent influenza vaccine: it is currently in the third phase of clinical trials, and it is expected to report production in 2020; 4) tetravalent combined vaccine: it is expected to complete the second phase of clinical trials, and it is expected to complete the third phase of clinical trials in 2020; 5) Four norovirus vaccines: in clinical preparation, global products; 6) component DPT: in clinical preparation; 7) smart investment: strategic layout of biological drugs, three monoclonal antibodies are in clinical stage, one cart begins clinical, and will enter clinical soon Hua Lan novel coronavirus is reported to have participated in the epidemic prevention and control through various forms since the outbreak of the new coronavirus pneumonia Novel coronavirus pneumonia was successfully launched in January 29th In January 29th, Hua Lan Biological Association jointly declared to the Henan provincial science and technology department the project of "Application of plasma therapy in severe new coronavirus pneumonia" According to the public information, Hualan biology is currently a research and development giant of blood products and vaccines in China The production scale, varieties and specifications, market coverage and production and sales volume of leading products of blood products rank first in the same industry in China In terms of vaccine, the vaccine company of Hualan biological group successfully developed the first domestic influenza a H1N1 vaccine in three months in 2009, and now it is a large-scale production base of Influenza Split Vaccine in China Novel coronavirus vaccine contract was signed in Liaoning, Liaoning, February 11th It is signed to cooperate with Tsinghua University School of Pharmacy (hereinafter referred to as Tsinghua college of Pharmacy) to develop a new cov vaccine contract According to the introduction, Chengdu University biology and Tsinghua University of pharmacy will jointly sign as joint applicants for clinical trials and production approval documents of new coronary peptide vaccine After obtaining the production approval documents, relevant technical achievements and intellectual property rights generated by the improved production process of Chengdu University biology belong to the company, and Chengdu University biology is the production unit of new coronary peptide vaccine Tsinghua pharmaceutical college has licensed the products, intellectual property rights, know-how, process technology, technical secrets, technical information and technical documents for the implementation of new coronary peptide vaccine by Chengdu University Biological Technology Co., Ltd., with a global scope Kangtai biology Kangtai is novel coronavirus vaccine Kangtai Bio said that in order to develop vaccines as early as possible, the company is promoting a number of technical routes On the one hand, it relies on its own inactivated vaccine and recombinant protein vaccine technology platform to develop a new crown vaccine On the other hand, Kangtai biology also cooperates with other institutions to develop a new generation of nucleic acid vaccine "But it will take more than a year to develop." As an innovative vaccine company with R & D expertise, kangxinuo bio has a strong R & D team, bringing together a number of scientists and vaccine industry experts For future development, conchino said it will focus on R & D, production and commercialization of innovative vaccines that meet Chinese and international quality standards The company rapidly promotes the research and development of a series of innovative vaccines, and the research and development pipeline covers the clinical urgently needed vaccines for the prevention of meningococcal, tuberculosis, pertussis, pneumonia, Ebola virus disease, herpes zoster and other indications With the help of new technology and previous experience, researchers can complete the early development of vaccine within two to three weeks after acquiring the virus sequence, and quickly enter the animal experiment stage At present, several products that have entered the animal experiment stage will probably enter the clinical trial stage around mid April at the earliest At present, some vaccine products with rapid progress have entered the stage of animal experiment From the data statistics, vaccine products entering the animal experiment stage mainly include recombinant protein vaccine, DNA vaccine and mRNA vaccine In addition, the author learned that overseas enterprises and universities, such as inovio pharmaceutical, Moderna company, the University of Queensland in Australia, Imperial College of technology in London and so on, have carried out new coronavirus vaccine development projects Among them, Imperial College London has announced that it has entered the stage of animal experiment